These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 826360)

  • 1. Activation of the alternative complement pathway in systemic lupus erythematosus.
    Wilson MR; Arroyave CM; Nakamura RM; Vaughan JH; Tan EM
    Clin Exp Immunol; 1976 Oct; 26(1):11-20. PubMed ID: 826360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum factors activating the alternative complement pathway in autoimmune disease: description of two different factors from patients with systemic lupus erythematosus.
    Arroyave CM; Wilson MR; Tan EM
    J Immunol; 1976 Mar; 116(3):821-6. PubMed ID: 815434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement activating cryoglobulins in the nephritis of systemic lupus erythematosus.
    Adu D; Williams DG
    Clin Exp Immunol; 1984 Mar; 55(3):495-501. PubMed ID: 6705265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.
    Perrin LH; Lambert PH; Miescher PA
    J Clin Invest; 1975 Jul; 56(1):165-76. PubMed ID: 1141431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement fixing properties of antibodies to double-stranded DNA in systemic lupus erythematosus.
    Gharavi AE; Elkon KB; Schifferli JA; Hughes GR
    J Clin Lab Immunol; 1981 Nov; 6(3):251-5. PubMed ID: 7338885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C3 metabolism in a patient with deficiency of the second component of complement (C2) and discoid lupus erythematosus.
    Wild JH; Zvaifler NJ; Müller-Eberhard HJ; Wilson CB
    Clin Exp Immunol; 1976 May; 24(2):238-48. PubMed ID: 1084239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative importance of C3b inactivator and beta 1H globulin in the modulation of the properdin amplification loop in systemic lupus erythematosus.
    Whaley K; Schur PH; Ruddy S
    Clin Exp Immunol; 1979 Jun; 36(3):408-14. PubMed ID: 114347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolism of the fifth component of complement, and its relation to metabolism of the third component, in patients with complement activation.
    Sissons JG; Liebowitch J; Amos N; Peters DK
    J Clin Invest; 1977 Apr; 59(4):704-15. PubMed ID: 845257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement cascade in systemic lupus erythematosus: analyses of the three activation pathways.
    Ceribelli A; Andreoli L; Cavazzana I; Franceschini F; Radice A; Rimoldi L; Sinico RA; Carlsson M; Wieslander J; Tincani A
    Ann N Y Acad Sci; 2009 Sep; 1173():427-34. PubMed ID: 19758182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease activity in the nephritis of systemic lupus erythematosus in relation to serum complement concentrations. DNA-binding capacity and precipitating anti-DNA antibody.
    Cameron JS; Lessof MH; Ogg CS; Williams BD; Williams DG
    Clin Exp Immunol; 1976 Sep; 25(3):418-27. PubMed ID: 1085678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-C1q antibodies and antiendothelial cell antibodies in systemic lupus erythematosus - relationship with disease activity and renal involvement.
    Oelzner P; Deliyska B; Fünfstück R; Hein G; Herrmann D; Stein G
    Clin Rheumatol; 2003 Oct; 22(4-5):271-8. PubMed ID: 14576989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation.
    Ross GD; Yount WJ; Walport MJ; Winfield JB; Parker CJ; Fuller CR; Taylor RP; Myones BL; Lachmann PJ
    J Immunol; 1985 Sep; 135(3):2005-14. PubMed ID: 4020137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hereditary C2 deficiency and systemic lupus erythematosus associated with severe glomerulonephritis.
    Roberts JL; Schwartz MM; Lewis EJ
    Clin Exp Immunol; 1978 Feb; 31(2):328-38. PubMed ID: 348363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.
    Kirou KA; Lee C; George S; Louca K; Peterson MG; Crow MK
    Arthritis Rheum; 2005 May; 52(5):1491-503. PubMed ID: 15880830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of alternative pathway and factor B haemolytic activities in patients with systemic lupus erythematosus: correlations with the alternative pathway regulatory proteins.
    Aguado MT; Perrin LH; Ramirez R; Miescher PA; Lambert PH
    Clin Exp Immunol; 1980 Dec; 42(3):495-505. PubMed ID: 6163579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative importance of C4 binding protein in the modulation of the classical pathway C3 convertase in patients with systemic lupus erythematosus.
    Daha MR; Hazevoet HM; Hermans J; van Es LA; Cats A
    Clin Exp Immunol; 1983 Oct; 54(1):248-52. PubMed ID: 6604610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late onset systemic lupus erythematosus and lupus-like disease in patients with apparent idiopathic glomerulonephritis.
    Adu D; Williams DG; Taube D; Vilches AR; Turner DR; Cameron JS; Ogg CS
    Q J Med; 1983; 52(208):471-87. PubMed ID: 6606818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement-mediated solubilization of immune complexes in systemic lupus erythematosus.
    Sakurai T; Fujita T; Kono I; Kabashima T; Yamane K; Tamura N; Kashiwagi H
    Clin Exp Immunol; 1982 Apr; 48(1):37-42. PubMed ID: 6979449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The autoantibody profile and disease activity in patients with systemic lupus erythematosus].
    Horák P; Hermanová Z; Faltýnek L; Pospísil Z; Scudla V
    Vnitr Lek; 1997 Oct; 43(10):639-44. PubMed ID: 9601876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of immune complex-mediated complement activation by autoantibodies (F-42) isolated from sera of patients with systemic lupus erythematosus.
    Daha MR; Hazevoet HM; Vanes LA
    Clin Exp Immunol; 1983 Sep; 53(3):541-6. PubMed ID: 6604604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.